GLMD
Companies
NASDAQ
Galmed Pharmaceuticals Ltd.
Health Care
$1.78
-$1.32 (-41.38%)
Price Chart
Overview
About GLMD
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Market Cap
$2.2M
Volume
210.7K
Avg. Volume
3.1M
P/E Ratio
-1.2330097
Dividend Yield
0.00%
Employees
15.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.42
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, GLMD shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.2M
Volume210.7K
P/E Ratio-1.23
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
April 5, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025